Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Amarin plc (NASDAQ:AMRN) announced new data presentations at the European Society of Cardiology (ESC) Congress from August 30 to September 2, 2024. The presentations focus on VASCEPA®/VAZKEPA® (icosapent ethyl) and its active ingredient, eicosapentaenoic acid (EPA). Key presentations include:
1. A REDUCE-IT® subgroup analysis on the effect of icosapent ethyl on cardiovascular events based on baseline small dense LDL cholesterol levels.
2. An examination of triglycerides' association with cardiovascular events in acute coronary syndrome patients.
3. An estimate of Spanish hospital patients eligible for icosapent ethyl treatment.
4. A study on EPA's effects on Lp(a) oxidation under high glucose conditions.
These presentations aim to enhance understanding of VASCEPA/VAZKEPA's clinical utility and mechanism of action in reducing residual cardiovascular risk.
Amarin plc (NASDAQ:AMRN) ha annunciato nuove presentazioni di dati al Congresso della Società Europea di Cardiologia (ESC) che si svolgerà dal 30 agosto al 2 settembre 2024. Le presentazioni si concentreranno su VASCEPA®/VAZKEPA® (icoapent etile) e il suo ingrediente attivo, l'acido eicosapentaenoico (EPA). Le presentazioni chiave includono:
1. Un'analisi di sottogruppo REDUCE-IT® sull'effetto dell'icoapent etile sugli eventi cardiovascolari in base ai livelli di colesterolo LDL denso e piccolo al basale.
2. Un'analisi dell'associazione dei trigliceridi con eventi cardiovascolari nei pazienti con sindrome coronarica acuta.
3. Una stima dei pazienti ospedalizzati spagnoli idonei al trattamento con icoapent etile.
4. Uno studio sugli effetti dell'EPA sull'ossidazione di Lp(a) in condizioni di alta glucosio.
Queste presentazioni mirano a migliorare la comprensione dell'utilità clinica e del meccanismo d'azione di VASCEPA/VAZKEPA nella riduzione del rischio cardiovascolare residuo.
Amarin plc (NASDAQ:AMRN) anunció nuevas presentaciones de datos en el Congreso de la Sociedad Europea de Cardiología (ESC) que se llevará a cabo del 30 de agosto al 2 de septiembre de 2024. Las presentaciones se centrarán en VASCEPA®/VAZKEPA® (éster etílico de icosapentano) y su ingrediente activo, el ácido eicosapentaenoico (EPA). Las presentaciones clave incluyen:
1. Un análisis de subgrupo de REDUCE-IT® sobre el efecto del éster etílico de icosapentano en eventos cardiovasculares según los niveles de colesterol LDL denso y pequeño al inicio.
2. Un examen de la asociación de los triglicéridos con eventos cardiovasculares en pacientes con síndrome coronario agudo.
3. Una estimación de los pacientes hospitalizados en España elegibles para tratamiento con éster etílico de icosapentano.
4. Un estudio sobre los efectos del EPA en la oxidación de Lp(a) en condiciones de alta glucosa.
Estas presentaciones tienen como objetivo mejorar la comprensión de la utilidad clínica y el mecanismo de acción de VASCEPA/VAZKEPA en la reducción del riesgo cardiovascular residual.
아마린 plc (NASDAQ:AMRN)은 2024년 8월 30일부터 9월 2일까지 열리는 유럽 심장학회 (ESC) 학술 대회에서 새로운 데이터 발표를 알렸습니다. 발표는 VASCEPA®/VAZKEPA® (이코사펜틸 에스터) 및 그 활성 성분인 EPA(이코사펜타메산)에 중점을 두고 있습니다. 주요 발표 내용은 다음과 같습니다:
1. REDUCE-IT® 하위 그룹 분석: 이코사펜틸 에스터가 기초의 소형 밀집 LDL 콜레스테롤 수치를 기반으로 한 심혈관 사건에 미치는 효과에 대한 연구.
2. 급성 심근증 환자의 심혈관 사건과 트리글리세리드 간의 연관성에 대한 검토.
3. 이코사펜틸 에스터 치료를 받을 수 있는 스페인 병원 환자 수의 추정.
4. 높은 포도당 상태에서 EPA가 Lp(a) 산화에 미치는 영향에 대한 연구.
이번 발표는 VASCEPA/VAZKEPA의 임상적 유용성과 잔여 심혈관 위험을 줄이는 작용 기전을 이해하는 데 도움을 주기 위한 목적으로 진행됩니다.
Amarin plc (NASDAQ:AMRN) a annoncé de nouvelles présentations de données au Congrès de la Société Européenne de Cardiologie (ESC), qui se tiendra du 30 août au 2 septembre 2024. Les présentations se concentreront sur VASCEPA®/VAZKEPA® (éthyl icosapent) et son ingrédient actif, l'acide eicosapentaénoïque (EPA). Les présentations clés incluent :
1. Une analyse de sous-groupe REDUCE-IT® sur l'effet de l'éthyl icosapent sur les événements cardiovasculaires en fonction des niveaux de cholestérol LDL dense et petit de référence.
2. Un examen de l'association entre les triglycérides et les événements cardiovasculaires chez les patients atteints de syndrome coronarien aigu.
3. Une estimation des patients hospitalisés en Espagne éligibles pour un traitement par éthyl icosapent.
4. Une étude sur les effets de l'EPA sur l'oxydation de Lp(a) dans des conditions de forte concentration en glucose.
Ces présentations visent à améliorer la compréhension de l'utilité clinique et du mécanisme d'action de VASCEPA/VAZKEPA dans la réduction du risque cardiovasculaire résiduel.
Amarin plc (NASDAQ:AMRN) kündigte neue Datenpräsentationen beim Europäischen Kardiologenkongress (ESC) an, der vom 30. August bis 2. September 2024 stattfindet. Die Präsentationen konzentrieren sich auf VASCEPA®/VAZKEPA® (Icosapentethyl) und dessen aktiven Inhaltsstoff, Eicosapentaensäure (EPA). Zu den wichtigsten Präsentationen gehören:
1. Eine REDUCE-IT® Subgruppenanalyse über die Auswirkungen von Icosapentethyl auf kardiovaskuläre Ereignisse basierend auf den Ausgangswerten von kleinen, dichten LDL-Cholesterinwerten.
2. Eine Untersuchung des Zusammenhangs zwischen Triglyceriden und kardiovaskulären Ereignissen bei Patienten mit akutem Koronarsyndrom.
3. Eine Schätzung der spanischen Krankenhauspatienten, die für eine Behandlung mit Icosapentethyl in Frage kommen.
4. Eine Studie über die Auswirkungen von EPA auf die Oxidation von Lp(a) bei hohen Glukosebedingungen.
Diese Präsentationen sollen das Verständnis der klinischen Nützlichkeit und des Wirkmechanismus von VASCEPA/VAZKEPA zur Reduzierung des verbleibenden kardiovaskulären Risikos vertiefen.
- Amarin is presenting new data on VASCEPA/VAZKEPA at a major cardiology conference, potentially increasing scientific and clinical interest
- The presentations cover various aspects of the drug's efficacy and mechanism, which could support its broader adoption
- Research includes subgroup analysis from the landmark REDUCE-IT trial, providing more detailed insights into the drug's effectiveness
- None.
This research presentation at the ESC Congress offers valuable insights into VASCEPA®/VAZKEPA® (icosapent ethyl) and its impact on cardiovascular health. The subgroup analysis of the REDUCE-IT® trial examining the effect of baseline small dense LDL cholesterol on icosapent ethyl's efficacy is particularly noteworthy. This could potentially identify specific patient groups who may benefit most from the treatment.
The study on triglycerides' association with cardiovascular events in acute coronary syndrome (ACS) patients could provide important information for risk stratification and treatment decisions. Additionally, the research on EPA's effect on Lp(a) oxidation under high glucose conditions may offer new mechanistic insights into how EPA provides cardiovascular benefits, especially relevant for diabetic patients.
These studies collectively enhance our understanding of VASCEPA®/VAZKEPA®'s mechanism of action and its potential role in managing residual cardiovascular risk. However, it's important to note that these are preliminary findings presented at a conference and full peer-reviewed publications will be necessary to fully assess their clinical implications.
The research presented at ESC 2024 provides valuable insights into the cardiovascular benefits of icosapent ethyl (IPE). The subgroup analysis of REDUCE-IT® based on baseline sdLDL-C levels could help identify patients who might derive the most benefit from IPE therapy, potentially leading to more targeted treatment strategies.
The study on triglycerides and cardiovascular risk in first vs. recurrent ACS is important for understanding the role of triglycerides in secondary prevention. This could influence treatment decisions for patients post-ACS, possibly expanding the use of triglyceride-lowering therapies like IPE.
The in vitro study on EPA's inhibition of Lp(a) oxidation under high glucose conditions is particularly intriguing. If confirmed in vivo, this could explain part of EPA's cardioprotective mechanism, especially in diabetic patients. These findings collectively strengthen the evidence base for IPE in cardiovascular risk reduction and may influence future treatment guidelines.
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.
The accepted abstracts include a REDUCE-IT subgroup analysis to assess if baseline small dense low density lipoprotein cholesterol (sdLDL-C) modifies the effect of icosapent ethyl (IPE) on cardiovascular events. A second abstract examines the association of triglycerides with cardiovascular events in patients with initial or recurrent acute coronary syndrome (ACS). A third abstract estimates the number of ACS patients eligible for IPE in Spanish hospitals, and finally, a fourth abstract measures the effects of EPA on oxidation of Lp(a) under experimental conditions of high glucose.
These data will be presented by a variety of international academic collaborators based on research or analyses supported by Amarin.
Featured Amarin-supported abstracts to be presented at ESC Congress 2024 include:
Oral Presentation
Icosapent Ethyl by Baseline Small Dense Low-Density Lipoprotein Cholesterol: An Analysis of REDUCE-IT
Rahul Aggarwal, MD, Deepak L. Bhatt, MD, MPH, P. Gabriel Steg, MD, Michael Miller, MD et al.
- Session Date & Time: August 30th from 13:45 to 15:00
- Location: Warsaw (Room)
Moderated Poster Presentations
Effect Of Triglycerides on Cardiovascular Risk in Patients with A First Vs. Recurrent Acute Coronary Syndrome
Alberto Cordero, Rosa Fernandez Olmo, Leticia A. Fernández-Friera, Sergio Manzano, et al.
- Session Date & Time: September 2nd from 12:00 to 12:50
- Location: Station 4
Estimate And Prognosis of Patients Who Are Candidates for Treatment with Eicosapentaenoic Acid After an Acute Coronary Syndrome
Alberto Cordero, Rosa Fernandez Olmo, Leticia A. Fernández-Friera, Sergio Manzano, et al.
- Session Date & Time: September 2nd from 12:00 to 12:50
- Location: Station 4
High Glucose Enhanced Lipoprotein(a) [Lp(a)] Oxidation in a Manner Inhibited by Eicosapentaenoic Acid (EPA) In Vitro
Samuel C.R. Sherratt, PhD, Peter Libby, MD, Richard L. Dunbar, MD, Deepak L Bhatt, MD, MPH, R. Preston Mason, PhD
- Session Date & Time: September 2nd from 15:00 to 15:50
- Location: Station 9
“At Amarin, we are committed to continuing to invest in research that helps clinicians further reduce additional residual cardiovascular risk for their patients beyond the management of LDL-C and other lipids and understand the added value of VASCEPA/VAZKEPA in reducing this residual cardiovascular risk for patients; we are also focused on and supporting research activities to understand the mechanism of action for IPE/EPA in this process,” said Nabil Abadir, MB. CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin. “These data at ESC help to achieve that, as well as enhance clinical understanding around the prevalence of residual cardiovascular risk associated with elevated triglyceride levels and around the mechanism of action of IPE/EPA, as well as providing additional validation of the clinical utility and value of VASCEPA/VAZKEPA for patients most at-risk of a cardiovascular event.”
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
About REDUCE-IT®
REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort). REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.[1] [2] These and other publications can be found in the Science section on the company’s website at www.amarincorp.com.
About VASCEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than ten million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, Germany, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA.
Indications and Limitation of Use (in the United States)
VASCEPA is indicated:
- As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
- established cardiovascular disease or
- diabetes mellitus and two or more additional risk factors for cardiovascular disease.
- As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
- VASCEPA was associated with an increased risk (
3% vs2% ) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter. - It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
- VASCEPA was associated with an increased risk (
12% vs10% ) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. - Common adverse reactions in the cardiovascular outcomes trial (incidence ≥
3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs3% ), peripheral edema (7% vs5% ), constipation (5% vs4% ), gout (4% vs3% ), and atrial fibrillation (5% vs4% ). - Common adverse reactions in the hypertriglyceridemia trials (incidence >
1% more frequent than placebo): arthralgia (2% vs1% ) and oropharyngeal pain (1% vs0.3% ). - Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.
FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s role concerning appropriate patients suffering from cardiovascular disease (CVD) and potential population health impact, as well as general beliefs about the safety and effectiveness of VASCEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (www.amarincorp.com/investor-relations), including but not limited to investor presentations, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
________________________
1 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.
2 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.
FAQ
What new data is Amarin (AMRN) presenting at the ESC Congress 2024?
When and where is the European Society of Cardiology (ESC) Congress 2024 where Amarin (AMRN) is presenting?
What is the focus of the REDUCE-IT subgroup analysis being presented by Amarin (AMRN)?
What is the purpose of Amarin's (AMRN) research presentations at the ESC Congress 2024?
